* If you want to update the article please login/register
Abstract \ nBackground \ nVisceral metastases account for 48-- 67% of metastatic breast cancer patients and presage an even worse overall survival. Previous study recommended prospective impact of nab-paclitaxel on patients with natural metastases subgroups. This phase II trial was performed to check out the effectiveness and safety of nab-paclitaxel in such a high-risk group of patients. Techniques \ nIn this prospective, single-center, open-label, phase II study, MBC patients with natural metastases received nab-paclitaxel. In univariate analysis, patients with premenopausal condition had a pattern of better treatment result. Multivariate evaluation demonstrated non brain metastasis and first line treatment as independent forecasters of longer PFS. Conclusions \ nThis phase II test recorded adequate efficacy and safety and security of nab-paclitaxel in MBC patients with natural metastases, providing evidence for relative professional practice. Patients in first line therapy had better treatment end result. This research study additionally showed the effectiveness and safety and security of 125 mg/m2 nab-paclitaxel among Asian patients.
Source link: https://doi.org/10.1186/s12885-021-08921-2
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions